ASLAN pounces on Array's deprioritised anticancer
This article was originally published in Scrip
The private Asian drug development firm ASLAN Pharmaceuticals has closed its first in-licensing deal, with Array BioPharma for an anticancer molecule with broad potential in solid tumour types.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.